A phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS)

被引：0
作者：
Bar-Or, Amit
Calabresi, Peter
Arnold, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd
Waubant, Emmanuelle
Gazda, Suzanne
Fox, Robert
Sarkar, Neena
Panzara, Michael
Smith, Craig
机构：
来源：
NEUROLOGY | 2007年 / 68卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
    Ralf Gold
    Ernst-Wilhelm Radue
    Gavin Giovannoni
    Krzysztof Selmaj
    Eva Havrdova
    Dusan Stefoski
    Till Sprenger
    Xavier Montalban
    Stanley Cohan
    Kimberly Umans
    Steven J. Greenberg
    Gulden Ozen
    Jacob Elkins
    BMC Neurology, 16
  • [22] Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
    Gold, Ralf
    Radue, Ernst-Wilhelm
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva
    Stefoski, Dusan
    Sprenger, Till
    Montalban, Xavier
    Cohan, Stanley
    Umans, Kimberly
    Greenberg, Steven J.
    Ozen, Gulden
    Elkins, Jacob
    BMC NEUROLOGY, 2016, 16
  • [23] Safety and efficacy with alemtuzumab over 13?years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
    Coles, Alasdair J.
    Achiron, Anat
    Traboulsee, Anthony
    Singer, Barry A.
    Pozzilli, Carlo
    Oreja-Guevara, Celia
    Giovannoni, Gavin
    Comi, Giancarlo
    Freedman, Mark S.
    Ziemssen, Tjalf
    Shiota, Debora
    Rawlings, Andreea M.
    Wong, Alana T.
    Chirieac, Magdalena
    Montalban, Xavier
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [24] Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review
    Siddiqui, Mohd Kashif
    Singh, Barinder
    Attri, Sumeet
    Veraart, Christiaan
    Harty, Gerard
    Wong, Schiffon L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (05) : 809 - 826
  • [25] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
    Sorensen, Per S.
    Lisby, Steen
    Grove, Richard
    Derosier, Frederick
    Shackelford, Steve
    Havrdova, Eva
    Drulovic, Jelena
    Filippi, Massimo
    NEUROLOGY, 2014, 82 (07) : 573 - 581
  • [26] A phase II open-label multicentre safety and efficacy study of oral recombinant ovine interferon tau administered daily in patients with relapsing-remitting multiple sclerosis
    Buckle, G.
    Bourdette, D.
    Waubant, E.
    Kachuck, N.
    Healy, B.
    Bakshi, R.
    Guttmann, C.
    Gilman, D.
    Liu, C.
    Weiner, H. L.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (09) : S122 - S122
  • [27] Oral laquinimod in patients with relapsing-remitting multiple sclerosis: clinical effects at 36 months in the open-label extension phase of the ALLEGRO study
    Comi, G.
    Jeffery, D.
    Kappos, L.
    Montalban, X.
    Boyko, A. N.
    Rocca, M. A.
    Filippi, M.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 218 - 218
  • [28] Baseline Characteristics of the ENSEMBLE Study Population: A Phase IIIb Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
    Carroll, W.
    Brochet, B.
    Patti, F.
    Buffels, R.
    Wei, W.
    Vollmer, T.
    Hartung, H. P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 475 - 475
  • [29] CONNECT: an open-label, active-controlled dimethyl fumarate study in pediatric patients with relapsing-remitting multiple sclerosis
    Maghzi, A. -H.
    Levin., S.
    Alroughani, R.
    Deiva, K.
    Pozzili, C.
    Lyons, J.
    Mokliatchouk, O.
    Pultz, J.
    N'Dure, F.
    Liu, S.
    Badwan, R.
    Branco, F.
    Franchimont, N.
    Hanna, J.
    Scaramozza, M.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 194 - 195
  • [30] Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart D.
    Rammohan, Kottil W.
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Musch, Bruno
    Greenberg, Steven J.
    NEUROLOGY, 2009, 73 (04) : 330 - 330
12345